said Tuesday that it expects to receive or seek regulatory approval for several drugs between 2005 and 2007.
The late-stage pipeline drugs include Entereg, a treatment for postoperative ileus (POI), a bowel disorder that occurs after abdominal and other types of surgery and can cause problems such as constipation, nausea and vomiting. POI can extend a patient's hospital stay.
GlaxoSmithKline said its clinical trials show the drug can speed up gastrointestinal recovery after surgery. The Food and Drug Administration is expected to rule on the company's application in late April.
The company described its prospects in a briefing for analysts and investors.
The company is also working with
to see if Entereg can reduce the constipation side-effects caused by high-strength painkillers called opioids. The drug is in clinical testing for this use, and the company said it expects to seek FDA approval in 2007.
GlaxoSmithKline is collaborating with another company,
, to develop a migraine treatment called Trexima. The companies expect to seek FDA approval during the second half of 2005.
GlaxoSmithKline also is seeking new uses for Lamictal, which is now sold as a treatment for epilepsy and bipolar disorder. The company is testing the drug as an add-on therapy for schizophrenia and an expanded treatment for bipolar disorder. Applications for additional indications should be filed in 2006 and 2007.
And the company expects to file with the FDA during the first half of next year an application for Requip/Adartel, a drug for restless leg syndrome. The drug was approved in France in July 2004. Restless leg syndrome is the third most common cause for disrupted sleep, the company says.
GlaxoSmithKline's stock was up 17 cents, or 0.4%, to $42.94 on Tuesday.